Search research articles
Contact Us
Filters
Showing results (31-40 of 78) with videos related to
Page
of 8
Sort By:
American Journal of Clinical Pathology
|
July 1, 1990
The recovery of Mycobacterium avium complex and Mycobacterium tuberculosis from blood specimens of AIDS patients using the nonradiometric BACTEC NR 660 medium
M R Motyl, B Saltzman, M H Levi, et al.
Antimicrobial Agents and Chemotherapy
|
April 25, 2012
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria
Elizabeth B Hirsch, Kimberly R Ledesma, Kai-Tai Chang, et al.
Antimicrobial Agents and Chemotherapy
|
July 29, 2005
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections
Mark J DiNubile, Joseph W Chow, Vilas Satishchandran, et al.
Jac-Antimicrobial Resistance
|
September 18, 2024
Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22
Mark G Wise, C Andrew DeRyke, Irina Alekseeva, et al.
International Journal of Antimicrobial Agents
|
January 29, 2022
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019
James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Journal of the Pediatric Infectious Diseases Society
|
January 9, 2025
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global Surveillance
C Andrew DeRyke, Mark G Wise, Karri A Bauer, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 21, 2023
Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021
Mark G Wise, James A Karlowsky, Wei-Ting Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 5, 2020
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017
James A Karlowsky, Sibylle H Lob, Janet Raddatz, et al.
Antibiotics (Basel, Switzerland)
|
October 28, 2025
Trends in <i>Pseudomonas aeruginosa</i> In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024
Mark G Wise, James A Karlowsky, Thales J Polis, et al.
Journal of Medical Microbiology
|
January 25, 2020
<i>In vitro</i> activity of imipenem-relebactam against resistant phenotypes of <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017
Sibylle H Lob, James A Karlowsky, Katherine Young, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 78) with videos related to
Sort By:
Page
of 8
American Journal of Clinical Pathology
|
July 1, 1990
The recovery of Mycobacterium avium complex and Mycobacterium tuberculosis from blood specimens of AIDS patients using the nonradiometric BACTEC NR 660 medium
M R Motyl, B Saltzman, M H Levi, et al.
Antimicrobial Agents and Chemotherapy
|
April 25, 2012
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria
Elizabeth B Hirsch, Kimberly R Ledesma, Kai-Tai Chang, et al.
Antimicrobial Agents and Chemotherapy
|
July 29, 2005
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections
Mark J DiNubile, Joseph W Chow, Vilas Satishchandran, et al.
Jac-Antimicrobial Resistance
|
September 18, 2024
Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22
Mark G Wise, C Andrew DeRyke, Irina Alekseeva, et al.
International Journal of Antimicrobial Agents
|
January 29, 2022
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019
James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Journal of the Pediatric Infectious Diseases Society
|
January 9, 2025
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global Surveillance
C Andrew DeRyke, Mark G Wise, Karri A Bauer, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 21, 2023
Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021
Mark G Wise, James A Karlowsky, Wei-Ting Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 5, 2020
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017
James A Karlowsky, Sibylle H Lob, Janet Raddatz, et al.
Antibiotics (Basel, Switzerland)
|
October 28, 2025
Trends in <i>Pseudomonas aeruginosa</i> In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024
Mark G Wise, James A Karlowsky, Thales J Polis, et al.
Journal of Medical Microbiology
|
January 25, 2020
<i>In vitro</i> activity of imipenem-relebactam against resistant phenotypes of <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017
Sibylle H Lob, James A Karlowsky, Katherine Young, et al.
Page
of 8